Cargando…
Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma
The foundation of precision immunotherapy in oncology is rooted in computational biology and patient-derived sample sequencing to enrich for and target immunogenic epitopes. Discovery of these tumor-specific epitopes through tumor sequencing has revolutionized patient outcomes in many types of cance...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037428/ https://www.ncbi.nlm.nih.gov/pubmed/33810617 http://dx.doi.org/10.3390/ijms22073455 |
_version_ | 1783677141203812352 |
---|---|
author | Lookian, Pashayar P. Zhao, David Medina, Rogelio Wang, Herui Zenka, Jan Gilbert, Mark R. Pacak, Karel Zhuang, Zhengping |
author_facet | Lookian, Pashayar P. Zhao, David Medina, Rogelio Wang, Herui Zenka, Jan Gilbert, Mark R. Pacak, Karel Zhuang, Zhengping |
author_sort | Lookian, Pashayar P. |
collection | PubMed |
description | The foundation of precision immunotherapy in oncology is rooted in computational biology and patient-derived sample sequencing to enrich for and target immunogenic epitopes. Discovery of these tumor-specific epitopes through tumor sequencing has revolutionized patient outcomes in many types of cancers that were previously untreatable. However, these therapeutic successes are far from universal, especially with cancers that carry high intratumoral heterogeneity such as glioblastoma (GBM). Herein, we present the technical aspects of Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) vaccine immunotherapy, an investigational therapeutic that potentially circumvents the need for in silico tumor-neoantigen enrichment. We then review the most promising GBM vaccination strategies to contextualize the MBTA vaccine. By reviewing current evidence using translational tumor models supporting MBTA vaccination, we evaluate the underlying principles that validate its clinical applicability. Finally, we showcase the translational potential of MBTA vaccination as a potential immunotherapy in GBM, along with established surgical and immunologic cancer treatment paradigms. |
format | Online Article Text |
id | pubmed-8037428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80374282021-04-12 Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma Lookian, Pashayar P. Zhao, David Medina, Rogelio Wang, Herui Zenka, Jan Gilbert, Mark R. Pacak, Karel Zhuang, Zhengping Int J Mol Sci Review The foundation of precision immunotherapy in oncology is rooted in computational biology and patient-derived sample sequencing to enrich for and target immunogenic epitopes. Discovery of these tumor-specific epitopes through tumor sequencing has revolutionized patient outcomes in many types of cancers that were previously untreatable. However, these therapeutic successes are far from universal, especially with cancers that carry high intratumoral heterogeneity such as glioblastoma (GBM). Herein, we present the technical aspects of Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) vaccine immunotherapy, an investigational therapeutic that potentially circumvents the need for in silico tumor-neoantigen enrichment. We then review the most promising GBM vaccination strategies to contextualize the MBTA vaccine. By reviewing current evidence using translational tumor models supporting MBTA vaccination, we evaluate the underlying principles that validate its clinical applicability. Finally, we showcase the translational potential of MBTA vaccination as a potential immunotherapy in GBM, along with established surgical and immunologic cancer treatment paradigms. MDPI 2021-03-26 /pmc/articles/PMC8037428/ /pubmed/33810617 http://dx.doi.org/10.3390/ijms22073455 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Review Lookian, Pashayar P. Zhao, David Medina, Rogelio Wang, Herui Zenka, Jan Gilbert, Mark R. Pacak, Karel Zhuang, Zhengping Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma |
title | Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma |
title_full | Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma |
title_fullStr | Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma |
title_full_unstemmed | Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma |
title_short | Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma |
title_sort | mannan-bam, tlr ligands, anti-cd40 antibody (mbta) vaccine immunotherapy: a review of current evidence and applications in glioblastoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037428/ https://www.ncbi.nlm.nih.gov/pubmed/33810617 http://dx.doi.org/10.3390/ijms22073455 |
work_keys_str_mv | AT lookianpashayarp mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma AT zhaodavid mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma AT medinarogelio mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma AT wangherui mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma AT zenkajan mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma AT gilbertmarkr mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma AT pacakkarel mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma AT zhuangzhengping mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma |